Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Jacobs

Showing results (51-60 of 258) with videos related to

Pageof 26
Sort By:
Clinics in Laboratory Medicine|June 5, 2004
Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patternsThomas M File, Michael S Benninger, Michael R Jacobs
The Journal of Antimicrobial Chemotherapy|February 4, 2003
Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobialsGlenn A Pankuch, Michael R Jacobs, Peter C Appelbaum
The Journal of Antimicrobial Chemotherapy|July 4, 2002
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agentsLois M Ednie, Michael R Jacobs, Peter C Appelbaum
The Journal of Antimicrobial Chemotherapy|May 15, 2003
In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time-killKim L Credito, Michael R Jacobs, Peter C Appelbaum
Diagnostic Microbiology and Infectious Disease|February 13, 2007
Oral beta-lactams applied to uncomplicated infections of skin and skin structuresMichael R Jacobs, Ronald N Jones, Philip A Giordano
Expert Review of Molecular Diagnostics|April 30, 2021
Recent advances in rapid antimicrobial susceptibility testing systemsMichael R Jacobs, Jordan D Colson, Daniel D Rhoads
Infectious Disease Clinics of North America|October 4, 2020
The Evolving Role of the Clinical Microbiology Laboratory in Identifying Resistance in Gram-Negative Bacteria: An UpdateAndrea Endimiani, Alban Ramette, Daniel D Rhoads, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2003
Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolatesMihaela Peric, Bülent Bozdogan, Michael R Jacobs, et al.
Journal of Clinical Medicine|December 1, 2020
The Mechanisms of Benefit of High-Flow Nasal Therapy in Stable COPDMassa Zantah, Aloknath Pandya, Michael R Jacobs, et al.
Clinics in Laboratory Medicine|June 5, 2004
Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infectionsDavid Andes, Jack Anon, Michael R Jacobs, et al.
Pageof 26

Showing results (51-60 of 258) with videos related to

Sort By:
Pageof 26
Clinics in Laboratory Medicine|June 5, 2004
Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patternsThomas M File, Michael S Benninger, Michael R Jacobs
The Journal of Antimicrobial Chemotherapy|February 4, 2003
Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobialsGlenn A Pankuch, Michael R Jacobs, Peter C Appelbaum
The Journal of Antimicrobial Chemotherapy|July 4, 2002
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agentsLois M Ednie, Michael R Jacobs, Peter C Appelbaum
The Journal of Antimicrobial Chemotherapy|May 15, 2003
In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time-killKim L Credito, Michael R Jacobs, Peter C Appelbaum
Diagnostic Microbiology and Infectious Disease|February 13, 2007
Oral beta-lactams applied to uncomplicated infections of skin and skin structuresMichael R Jacobs, Ronald N Jones, Philip A Giordano
Expert Review of Molecular Diagnostics|April 30, 2021
Recent advances in rapid antimicrobial susceptibility testing systemsMichael R Jacobs, Jordan D Colson, Daniel D Rhoads
Infectious Disease Clinics of North America|October 4, 2020
The Evolving Role of the Clinical Microbiology Laboratory in Identifying Resistance in Gram-Negative Bacteria: An UpdateAndrea Endimiani, Alban Ramette, Daniel D Rhoads, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2003
Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolatesMihaela Peric, Bülent Bozdogan, Michael R Jacobs, et al.
Journal of Clinical Medicine|December 1, 2020
The Mechanisms of Benefit of High-Flow Nasal Therapy in Stable COPDMassa Zantah, Aloknath Pandya, Michael R Jacobs, et al.
Clinics in Laboratory Medicine|June 5, 2004
Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infectionsDavid Andes, Jack Anon, Michael R Jacobs, et al.
Pageof 26